CURRENT ISSUE Current Issue Cover
VOL 8 • NO 7 NOV/DEC 2017
IN THIS ISSUE

Innovations in Cancer Therapies and Rising Costs

Pamela Hallquist Viale, RN, MS, CNS, ANP



Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies

Ali McBride,(1) PharmD, MS, BCPS, BCOP, Steven Trifilio,(2) RPh, Nadine Baxter,(3) MNSc, APN-BC, AOCNP®, Tara K. Gregory,(4) MD, and Scott C. Howard,(5) MD, MS

 
Section Seperator

TODAY'S NEWS

ASH 2017: Clinical Activity Seen With An...

A one-time infusion of an investigational chimeric...

ASH 2017: JULIET Trial: 6-Month Analysis...

Six months after receiving a single dose of tisage...

ASH 2017: ZUMA-1: Responses to CAR T-Cel...

Among 108 patients with fast-growing and refractor...

Study Suggests Racial Differences in Lun...

A study by Mitchell et al published in Clinical Ca...

Identification of Cystic Precursors to P...

In a study reported in the Journal of Clinical Onc...

More News From Today More News
Section Seperator

EDITORIALS & COMMENTARY

Lenalidomide-Associated Cytopenias in MDS

A male patient aged 67 years with a 2-year history of refractory anemia and myelodysplastic syndromes..

Anaplastic Lymphoma Kinase Inhibitors for NSCLC

Lung cancer is the second most commonly diagnosed cancer in the U.S., with an estimated 222,500 new cases in 2017...

Li-Fraumeni Syndrome

Li-Fraumeni syndrome is a rare inherited autosomal-dominant disorder that is manifested by a wide range of malignancies that appear at an unusually early age...

Immunotherapy Through the Years

Immunotherapy’s use in oncology has emerged in recent years as an important treatment option in many different disease sites...

Lenvatinib for Thyroid Cancer and Advanced RCC

Differentiated thyroid cancer (DTC) is a malignancy that is occurring with greater frequency...

More Editorials & Commentary More Tweets
 
Section Seperator

PREVIOUS HIGHLIGHTS

ASH 2017: Rapid Responses, Few Adverse E...

In a phase I trial, patients with an advanced or a...

ASH 2017: CLARITY Trial: Combination Tre...

One-third of patients with previously treated chro...

ASH 2017: Addition of Brentuximab Vedoti...

Patients with advanced Hodgkin lymphoma (HL) who w...

ASH 2017: Targeted Antibody Mogamulizuma...

In a phase III trial presented by Kim et al, patie...

ASH 2017: Sustained Benefit With Ibrutin...

The results of a pooled analysis of patients with ...

More Highlights More Highlights
Section Seperator

LATEST TWEETS







More Tweets More Tweets
 
Section Seperator
Section Seperator
 
 
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here